Source: mCig, Inc.

VitaCig, Inc. Launches $2 Nicotine-Free eCig Emitting Flavorful Vapor + Vitamins

-- Nicotine-Free Tobacco-Free Smokeless Alternative to Traditional Cigarettes

-- Simply Vitamins + Natural Flavors Conveniently Vaporized by an eCig-like Device

-- Three Great Flavor Combinations: Relax, Refresh, Energize

-- Additional Medical and Nutritional Applications In the Pipeline

BELLEVUE, Wash., April 15, 2014 (GLOBE NEWSWIRE) -- mCig, Inc. (OTCQB:MCIG) is pleased to announce that its wholly owned subsidiary VitaCig, Inc. has officially launched its flagship product: "VitaCig".

The VitaCig is an innovative $2 device that is nicotine-free and smokeless. Instead of harmful toxins, the VitaCig emits flavorful vapor comprised of vitamins, natural supplements, and organic flavors. The VitaCig experience is unique and encompasses everything you love (or loved) about smoking without the things you don't. No tobacco smoke or cigarette smell. No more harmful tar, and no nicotine, just vitamins + flavored vapor delivered in a sleek metallic casing that looks and feels like an eCig.

The VitaCig comes in three great flavor combinations: Relax, Refresh, and Energize. Order one today by visiting:

VitaCig Video Ad

The company recently released a video advertisement for the VitaCig which can be found here:

The Science Behind VitaCig*

The VitaCig device is designed to deliver vitamins and phytonutrients via direct inhalation of rapidly absorbed vapor. Phytonutrients are compounds found in plants that provide significant health benefits. Every VitaCig includes the following base Vitamins: A, B, C, E, and CoQ10 (Ubidecarenone).


The "end of the day" VitaCig that can be enjoyed after a long day at work or before bed-time. Extracts of blueberry and black currant provide flavor as well as the potent anti-inflammatory and antioxidant phytonutrients known as polyphenols and anthocyanins. B-Myrcene belongs to a class of aromatic plant compounds called monoterpenes and is incorporated for its sedative, muscle relaxant and analgesic properties.


The "go-to" VitaCig that can be enjoyed throughout the day for a refreshing and uplifting feeling. Oils of peppermint and spearmint provide flavor and a natural source of menthol. Menthol, a monterpene derivative, has analgesic, local anesthetic, decongestant, expectorant and cooling properties. Eucalyptol belongs to a class of aromatic plant compounds known as oxides and has expectorant, decongestant, antiseptic, bronchodilatory and cough suppressant properties.


The calorie-free "energy booster" that will help you get through a slow day. Extracts of orange and grapefruit provide flavor, vitamin C and citrus bioflavonoids. Citrus bioflavonoids have been shown to provide antioxidant protection and immune system support. Orange oil is added for flavor and as a natural source of limonene. Limonene is a monoterpene incorporated for its stimulating, uplifting, antiseptic, and anxiolytic properties.

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. 

VitaCig and Future Electronic Cigarette Regulation

VitaCig, Inc. management believes that the VitaCig should not be classified as an electronic cigarette ("eCig"). With the exception of certain design elements, the VitaCig bears little technical resemblance to traditional nicotine-based eCigs. The VitaCig delivers a vapor that contains a mix of natural flavors and vitamins as opposed to nicotine, a regulated substance. The company is closely monitoring regulatory developments within the Electronic Cigarette Industry and is committed to operating with best industry practices. More explicitly, if guidelines or regulations are published that require standardization of components or testing for electronic cigarette like devices, VitaCig will be the first to abide by such regulations. In lieu of such guidelines, VitaCig is proud to have its products manufactured in facilities that abide by current globally accepted best industry standards such as: Restriction of Hazardous Substance Directive (RoHS) and European CE conformity marking.   

VitaCig, Inc. Dividend and IPO

The VitaCig, Inc. Spin-Off, Dividend, and IPO remains on schedule. The company will be filing the S1 Prospectus with the Securities and Exchange Commission by April 20th, 2014.

About VitaCig, Inc.

VitaCig, Inc. is a technology company that is harnessing mobile vaporization technology for medical delivery applications. The company has launched its first consumer product: The VitaCig, a $2 nicotine-free device that looks and feels like an electronic cigarette (eCig). Unlike a traditional eCig, the VitaCig delivers a vapor of natural flavors, vitamins, and phytonutrients. Initially the VitaCig will be produced in three flavor categories: Relax, Refresh, Energize with plans for additional flavor categories and targeted medical applications in the future. The company is currently a subsidiary of mCig, Inc. (Stock Symbol: MCIG) that is in the process of being spun-off to shareholders.

The traditional tobacco industry is estimated at nearly $900 Billion a year. Financial analysts from Wells Fargo, Goldman Sachs, and Citigroup predict that by 2022 Electronic Cigarettes will supplant the traditional tobacco industry and eventually grow into a $1 Trillion industry.

VitaCig is disrupting both the traditional tobacco industry and the growing electronic cigarette industry by appealing to the existing 1.2 Billion adults globally that smoke cigarettes, providing them with a nicotine and tobacco-free alternative that may assist in harm reduction. Moreover, the company is expanding the target market beyond the 1.2 Billion adults by appealing to non-smokers or occasional smokers with a superior method for the consumption of Vitamins, Nutrients, and other compounds with medicinal efficacy. – To learn more visit:

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.

Paul Rosenberg